Policy & Regulation
Genmab receives marketing authorisation in Europe for DARZALEX (Daratumumab) in combination with lenalidomide and dexamethasone in frontline multiple myeloma
20 November 2019 - Genmab A/S (CPH:GMAB), a biotechnology company specialising in the creation and development of differentiated antibody therapeutics for the treatment of cancer, announced on Tuesday...
Oncopeptides widens loss in Q3 2019
20 November 2019 - Oncopeptides AB (STO:ONCO) reported on Tuesday that it recorded a loss of SEK189.78m, or SEK3.53 per share, for the third quarter of 2019, from 1 July 2019 to 30 September 2019.This...
ORION-10 Study of Inclisiran in ASCVD Patients Showed Durable and Potent Lowering of LDL-C with Twice-Yearly Dosing
19 November 2019 - - US-based pharmaceutical company The Medicines Company (NASDAQ: MDCO) has released detailed results from ORION-10, the second of three pivotal 18-month low-density lipoprotein chol...
KarXT Met Primary Endpoint in Phase 2 Clinical Trial of Acute Psychosis in Patients with Schizophrenia
19 November 2019 - - US-based clinical-stage biopharmaceutical company Karuna Therapeutics, Inc. (NASDAQ: KRTX) has received results from its Phase 2 clinical trial of KarXT for the treatment of acute...
Consistent Effects of Farxiga in Heart Failure Patients with Reduced Ejection Fraction Shown in New Analyses from Landmark Phase III DAPA-HF Trial
19 November 2019 - - British-Swedish pharmaceutical company AstraZeneca (OTC: AZNCF) released new data from five additional analyses of the landmark Phase III DAPA-HF trial, which showed that Farxiga ...
Aveo Presents Updated OS and Subgroup Data from Phase 3 TIVO-3 Trial of Tivozanib in Renal Cell Carcinoma
19 November 2019 - - US-based biopharmaceutical company Aveo Oncology (NASDAQ: AVEO) has presented updated data from the Phase 3 TIVO-3 trial.
The data were presented on Saturday, November 16, ...